Tauklarify (florquinitau F 18) is a brain PET tracer that lights up tau tangles, twisted tau deposits tied to Alzheimer's, while Alzheimer's blood tests measure p-tau217 signals to estimate amyloid likelihood. In 2026 memory clinics use blood tests for initial triage and reserve Tauklarify PET to identify tau pathology and map its spread when diagnosis or care decisions stay unclear.
Tauklarify was approved August 14, 2026 for PET imaging in cognitively impaired adults evaluated for Alzheimer's, according to NeurologyLive reporting on the FDA approval notice. Blood tests came first and reach more clinics, but they answer a narrower question. Understanding that difference helps patients read results without overreading them.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does each test measure?
- How do you read positive and negative results?
- When does a blood test need PET or spinal fluid confirmation?
- What should memory clinic patients ask?
- Who is each test intended for?
What does each test measure?
Blood p-tau217 tests estimate the likelihood of amyloid pathology, a key Alzheimer's marker. A high value raises concern for Alzheimer's biology. A low value lowers it. Tauklarify PET shows tau tangle pathology in the brain itself.
It helps clinicians see whether tau is present and how widely it has spread. Blood tests do not stage tau spread, measure dementia severity, or prove that symptoms come from Alzheimer's. Think of blood testing as a screen and tau PET as a locator. One points toward Alzheimer's biology. The other places tau on a brain map.
How do you read positive and negative results?
A positive Tauklarify scan means tau pathology was visually detected. A negative scan means it was not detected. Neither result is absolute because a negative scan does not exclude tau pathology and a positive scan does not confirm it by itself. Reader agreement was strong in the pivotal study, with 68%-88% positive agreement, 93%-99% negative agreement, and Fleiss kappa of 0.86-0.92 across five readers. That pattern means negative tau PET readings were more consistent than positive readings.
Clinicians therefore pair the image with history, exams, cognitive testing, and often amyloid results. Blood results work in the same paired way. The Alzheimer's Association 2025 guideline endorses accurate blood tests with at least 90% sensitivity and 75% specificity for triage in specialty care, not as replacements for PET or spinal fluid, as described in the Association guideline summary. A clearly normal or clearly abnormal result guides next steps. An intermediate result means wait and confirm.
When does a blood test need PET or spinal fluid confirmation?
Discordant results need a second look. Examples include a positive blood test with an atypical clinical picture, a negative blood test despite progressive amnestic impairment, or mixed test results over time. Kidney impairment also complicates blood interpretation because reduced clearance can raise p-tau values. Indeterminate blood results need confirmation too.
The first FDA-cleared blood aid, the Lumipulse pTau217 to beta-amyloid 1-42 plasma ratio for patients 55 and older with signs and symptoms, was cleared May 16, 2025, according to the FDA clearance announcement. Later blood tests added rule-in and rule-out claims, but they still leave staging unanswered. Tau PET or cerebrospinal fluid testing resolves those gaps. PET can clarify tau burden before anti-amyloid therapy, differential diagnosis, or clinical trial screening. Spinal fluid remains an option when PET is unavailable or unsafe.
What should memory clinic patients ask?
Bring medication, kidney disease, and prior biomarker history to the visit. Ask how the ordered test changes diagnosis, treatment eligibility, or follow-up. Ask what cutoff, category, or visual read was used.
Write down the exact test name and result category. Blood p-tau217 assays differ by maker and intended use. Tauklarify is specific to tau PET and is not established for non-Alzheimer tau diseases.
- Is my impairment objectively measured and documented for this test?
- Does my blood result fall clearly normal, clearly abnormal, or in between?
- Would tau PET change treatment, trial, or care planning for me?
- Do kidney problems, other brain diseases, or medicines affect my result?
- What confirmatory test do you recommend, and how soon?
Who is each test intended for?
Blood biomarker testing fits adults with objective cognitive impairment seen in specialized care. It is not meant for worried but unimpaired adults seeking general screening. The intended age group for cleared blood tests starts at 55 with cognitive signs or complaints.
Tauklarify fits cognitively impaired adults already being evaluated for Alzheimer's. The referral often follows an unclear cause, possible Alzheimer's, or a need to assess tau before therapy. Primary care doctors may order selected blood tests, then refer positive, uncertain, or complex cases for PET. Ask your clinic whether it reads tau PET on site or refers out.
You Might Also Like
- Tauklarify Tau PET vs Alzheimer’s Blood Tests in 2026: How Memory Clinic Patients Can Compare Testing Options
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: Result Interpretation Questions for Memory Clinic Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: Result Interpretation Questions for Memory Clinic Patients
